Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $481.56M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.12M
Average 0.17M
Returns on capital
Monopar Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-10.0%
avg -63.6%
ROIC
-12.1%
avg -64.8%
ROA
-9.7%
avg -56.3%
Analysis
ROA is currently the strongest return metric at -9.7% versus its period average of -56.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Chandler D. Robinson | Co-Founder, Chief Executive Officer, President & Director | USD 1.67M | 42 | — | — |
Andrew J. Cittadine | Chief Operating Officer | USD 985K | 54 | — | — |
Quan Anh Vu | CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer | USD 623.51K | 54 | 2.65K | 0.04% |
Christopher Starr | Co-Founder & Independent Executive Chairman of the Board | USD 200K | 74 | — | — |
Jeffrey D. Kent FACG FACP | Executive Vice President of Head of Medical Affairs | — | 64 | — | — |
Susan Rodriguez | Chief Commercial & Strategy Officer | — | 64 | 0 | <0.01% |
Patrice Rioux | Acting Chief Medical Officer | — | 75 | 0 | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$104,925.00
Sells
36
$5.68M
Net Transaction Value
−$5.57M
Net selling
Most Active
Tsuchimoto Kim R
16 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 4, 26Nov 4, 2026 | Tsuchimoto Kim R Direct | Sell | $91.6K$91,621.25 |
| Nov 4, 26Nov 4, 2026 | Tsuchimoto Kim R Direct | Sell | $71.1K$71,064.60 |
| Nov 4, 26Nov 4, 2026 | Tsuchimoto Kim R Direct | Sell | $43.3K$43,326.00 |
| Nov 2, 26Nov 2, 2026 | Tsuchimoto Kim R Direct | Sell | $84K$84,049.90 |
| Nov 2, 26Nov 2, 2026 | Anderson Raymond Direct | Sell | $105.2K$105,200.08 |
| Nov 2, 26Nov 2, 2026 | Anderson Raymond Direct | Sell | $13.7K$13,736.00 |
| Nov 2, 26Nov 2, 2026 | Anderson Raymond Direct | Sell | $40.2K$40,236.00 |
| Nov 2, 26Nov 2, 2026 | Anderson Raymond Direct | Sell | $55.6K$55,574.40 |
| Oct 1, 26Oct 1, 2026 | STARR CHRISTOPHER M Direct | Sell | $361.6K$361,634.79 |
| Oct 1, 26Oct 1, 2026 | STARR CHRISTOPHER M Direct | Sell | $234.1K$234,095.40 |
1–10 of 37
Summary
Insiders reported 1 buys worth $104,925.00 and 36 sells worth $5.68M over the last 12 months. That adds up to net selling of $5.57M. Tsuchimoto Kim R was the most active insider with 16 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Monopar Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about MNPR's management, answered from reported figures.
Who manages MNPR?
Monopar Therapeutics Inc. (MNPR) lists 7 active executives. The top listed executive is Chandler D. Robinson, Co-Founder, Chief Executive Officer, President & Director.
Are MNPR insiders buying or selling?
Recent insider activity shows net selling of $32.45M.
Continue the stock analysis
Jump to another research area for this company.